Wolf R. Wiedemeyer

Biology Director

Dr. Wolf R. Wiedemeyer is a cancer biologist with more than 12 years of experience in basic and translational cancer research, both as a principal investigator in the academic setting and, most recently, as a Principal Scientist in Oncology Discovery at AbbVie. He has extensive experience leading and working in cross-functional teams that integrate functional and bioinformatic approaches to identify novel oncology targets and to elucidate mechanisms of response and resistance to therapeutic agents. At AbbVie, he was the discovery lead for several antibody-drug conjugates (ADCs) in early clinical trials and his team supported the early pipeline by managing and characterizing patient-derived xenograft (PDX) models representing different solid tumor indications, including SCLC, NSCLC, CRC and OV.

Prior to joining AbbVie, Dr. Wiedemeyer was a research scientist and assistant professor at Cedars-Sinai Medical Center/UCLA, where his lab studied mechanisms of chemoresistance in high-grade serous ovarian cancer and basal-like breast cancer, as well as patterns of response and resistance to cyclin-dependent kinase (CDK) inhibitors.

Dr. Wiedemeyer obtained his doctoral degree from the German Cancer Research Center and worked as a postdoc at the Dana-Farber Cancer Institute in Boston. He was a contributing author on The Cancer Genome Atlas (TCGA) pilot project in glioblastoma.